AI mRNA candidate shows early promise in lung fibrosis
A therapeutic candidate which operates through a novel mRNA biology mechanism of action could open new avenues for treating idiopathic pulmonary fibrosis (IPF) patients. Anima Biotech has identified a preclinical candidate, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts’… Read More